Mednet Logo
CommunityRheumatology

Would you add romosozumab to denosumab for a year or switch to romosozumab for a year in a patient who fractures on long term denosumab therapy?

1 Answer
Mednet Member
Mednet MemberInvited Expert
Rheumatology · Icahn School of Medicine at Mount Sinai
Answered on
  • My preference, if insurance was not an obstacle, would be to add romo rather than switch. The data are limited and certainly this is "off label" but the rationale is reasonable. Denosumab treatment leads to increased sclerostin levels which would be targeted by the addition of Romo; furthermore thi...

Join for free or sign in to see the full answer